{"id":915,"date":"2025-05-15T01:41:21","date_gmt":"2025-05-15T08:41:21","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=915"},"modified":"2025-05-15T02:08:43","modified_gmt":"2025-05-15T09:08:43","slug":"cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/","title":{"rendered":"\u62e8\u5eb7\u89c6\u4e91\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u521b\u65b0\u836fCBT-004\u5728\u7f8e\u56fd\u5b8c\u6210\u4e34\u5e8aII\u671f\u5b9e\u9a8c"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"915\" class=\"elementor elementor-915\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-cd3c55c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"cd3c55c\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-105abb5\" data-id=\"105abb5\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a6fe7a9 elementor-widget elementor-widget-heading\" data-id=\"a6fe7a9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">\u62e8\u5eb7\u89c6\u4e91\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u521b\u65b0\u836fCBT-004\u5728\u7f8e\u56fd\u5b8c\u6210\u4e34\u5e8aII\u671f\u5b9e\u9a8c<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ba0fe9b elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ba0fe9b\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c235a1d\" data-id=\"c235a1d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5bd6544 elementor-widget elementor-widget-text-editor\" data-id=\"5bd6544\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"MsoNormal\"><span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; mso-fareast-font-family: \u5fae\u8f6f\u96c5\u9ed1; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;\">\u773c\u79d1\u521b\u65b0\u836f\u4f01\u62e8\u5eb7\u89c6\u4e91 \uff08Cloudbreak Pharma Inc.\uff09\u7ba1\u7ebf\u4e2d\u7528\u4e8e\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\uff08\u53c8\u79f0\u5145\u8840\u6027\u7ed3\u819c\u9ec4\u6591\uff09\u7684CBT-004\u4e8e4\u6708\u5728\u7f8e\u56fd\u5b8c\u6210\u4e34\u5e8aII\u671f\u5b9e\u9a8c\u3002\u521d\u6b65\u7ed3\u679c\u663e\u793a\u773c\u90e8\u5b89\u5168\u6027\u4f18\u5f02\uff0c\u6709\u6548\u6027\u7684\u4e3b\u8981\u7ec8\u70b9\u8fbe\u5230\u8bbe\u8ba1\u8981\u6c42\uff0c\u591a\u9879\u6b21\u8981\u7ec8\u70b9\u4e5f\u8fbe\u5230\u8bbe\u8ba1\u8981\u6c42\u3002<\/span><\/p><p class=\"MsoNormal\"><span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; mso-fareast-font-family: \u5fae\u8f6f\u96c5\u9ed1; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;\">\u62e8\u5eb7\u89c6\u4e91\u662f\u4e00\u5bb6\u521b\u65b0\u9a71\u52a8\u7684\u4e34\u5e8a\u773c\u79d1\u751f\u7269\u6280\u672f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u5f00\u53d1\u521b\u65b0\u6027\u53ca\u5dee\u5f02\u5316\u7597\u6cd5\u3002\u62e8\u5eb7\u89c6\u4e91\u4e8e2015\u5e74\u5728\u7f8e\u56fd\u6210\u7acb\uff0c\u9664\u8bbe\u7acb\u5728\u52a0\u5dde\u5c14\u6e7e\u7684\u603b\u90e8\u5916\uff0c\u5728\u4e2d\u56fd\u5927\u9646\u548c\u4e2d\u56fd\u9999\u6e2f\u4e5f\u6709\u5efa\u7acb\u8fd0\u8425\u673a\u6784\u516c\u53f8\u81f4\u529b\u4e8e\u81ea\u4e3b\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u56fd\u9645\u9996\u521b\u6216\u8005\u540c\u7c7b\u4e2d\u6700\u4f73\u7684\u773c\u79d1\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u62e8\u5eb7\u89c6\u4e91\u5df2\u5efa\u7acb\u4e86\u5e7f\u6cdb\u4e14\u521b\u65b0\u7684\u7ba1\u7ebf\u5305\u62ec\u516b\u79cd\u836f\u7269\u5019\u9009\u7269\uff0c\u6db5\u76d6\u773c\u7403\u524d\u540e\u90e8\u7684\u4e3b\u8981\u75be\u75c5\uff0c\u5176\u4e2d\u56db\u6b3e\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\uff0c\u56db\u6b3e\u5904\u4e8e\u4e34\u5e8a\u524d\u9636\u6bb5\u3002<\/span><\/p><p class=\"MsoNormal\"><span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; mso-fareast-font-family: \u5fae\u8f6f\u96c5\u9ed1; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;\">CBT-004\u662f\u4e00\u79cd\u5c40\u90e8\u6ef4\u773c\u6db2\uff0c\u91c7\u7528\u591a\u6fc0\u9176\u6291\u5236\u5242\uff0c\u9776\u5411\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u53ca\u8840\u5c0f\u677f\u884d\u751f\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff0c\u9002\u7528\u4e8e\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u3002 <\/span><span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; mso-fareast-font-family: \u5fae\u8f6f\u96c5\u9ed1; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;\">targeting VEGFRs and PDGFRs, is formulated as a topical ocular eyedrop indicated for the treatment of vascularised pinguecula.<\/span><\/p><p class=\"MsoNormal\"><span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; mso-fareast-font-family: \u5fae\u8f6f\u96c5\u9ed1; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;\">\u7751\u88c2\u6591\u662f\u4e00\u79cd\u5706\u5f62\u3001\u6de1\u9ec4\u8272\u7684\u9686\u8d77\u7ec4\u7ec7\uff0c\u957f\u5728\u89d2\u819c\u9644\u8fd1\u7684\u7ed3\u819c\u4e0a\u3002\u4e00\u822c\u800c\u8a00\uff0c\u65e0\u75c7\u72b6\u7684\u7751\u88c2\u6591\u65e0\u9700\u6cbb\u7597\uff0c\u4f46\u5176\u6de1\u9ec4\u8272\u548c\u9686\u8d77\u7684\u8f6e\u5ed3\u53ef\u80fd\u4f1a\u5f15\u8d77\u673a\u68b0\u6027\u6216\u4e0e\u6cea\u819c\u4e0d\u826f\u6709\u5173\u7684\u773c\u8868\u523a\u6fc0\u3002\u7d2b\u5916\u7ebf\u7684\u7d2f\u79ef\u7167\u5c04\u662f\u5bfc\u81f4\u7751\u88c2\u6591\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u5f53\u75c5\u53d8\u90e8\u4f4d\u51fa\u73b0\u8840\u7ba1\u5316\u6216\u53d1\u708e\u65f6\uff0c\u53ef\u80fd\u4f1a\u5bfc\u81f4\u773c\u90e8\u5145\u8840\u3001\u4e0d\u9002\u3001\u75bc\u75db\u3001\u5f02\u7269\u611f\u3001\u6d41\u6cea\u548c\u75d5\u75d2\u7b49\u75c7\u72b6\u3002\u76ee\u524d\u5e76\u65e0\u83b7\u7f8e\u56fd\u836f\u7ba1\u5c40\u6279\u51c6\u9002\u7528\u4e8e\u8840\u7ba1\u5316\u7751\u88c2\u6591\u7684\u836f\u7269\u7597\u6cd5\u3002<\/span><\/p><p class=\"MsoNormal\"><span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; font-family: '\u5fae\u8f6f\u96c5\u9ed1',sans-serif; mso-bidi-font-family: \u5fae\u8f6f\u96c5\u9ed1;\">CBT-004\u4e8e2023\u5e749\u6708\u9012\u4ea4\u7f8e\u56fd\u836f\u76d1\u5c40\u7533\u8bf7\u5e76\u83b7\u6279\u8fdb\u884c\u6cbb\u7597\u8840\u7ba1\u5316\u7751\u88c2\u6591\u7684\u4e34\u5e8aII\u671f\u7814\u7a76\u3002\u6b64\u9879\u4e34\u5e8a\u5b9e\u9a8c\u5df2\u4e8e2025\u5e744\u6708\u5728\u7f8e\u56fd\u5b8c\u6210\u3002\u521d\u6b65\u6570\u636e\u5206\u6790\u663e\u793aCBT-004\u773c\u90e8\u5b89\u5168\u6027\u4f18\u5f02\u3002\u6b64\u9879\u7814\u7a76\u7684\u4e34\u5e8a\u6709\u6548\u6027\u4e3b\u8981\u7ec8\u70b9\u4e3a\u773c\u90e8\u7ed3\u819c\u7ea2\u80bf\u3002\u6b64\u9879\u6307\u6807\u8fbe\u5230\u4e86\u9884\u671f\u7ed3\u679c\u3002\u4e24\u7ec4CBT-004\u7528\u836f\u7ec4\u4e0e\u5b89\u6170\u5242\u7ec4\u76f8\u6bd4\uff0c\u7ed3\u819c\u7ea2\u80bf\u5206\u6570\u90fd\u6709\u663e\u8457\u4e0b\u964d\uff0c\u5e76\u8fbe\u5230\u7edf\u8ba1\u5b66\u5dee\u5f02\u3002\u4e8e\u6b64\u540c\u65f6\uff0c\u5242\u91cf\u6548\u679c\u7684\u76f8\u5173\u6570\u636e\u663e\u793a\uff0c\u9ad8\u5242\u91cf\u7ec4\u4f18\u4e8e\u4f4e\u5242\u91cf\u7ec4\u3002\u6b64\u5916\uff0c\u591a\u9879\u6709\u6548\u6027\u6b21\u8981\u6307\u6807\uff0c\u7528\u836f\u7ec4\u548c\u5b89\u6170\u5242\u7ec4\u5bf9\u6bd4\u4e5f\u8fbe\u5230\u7edf\u8ba1\u5b66\u5dee\u522b\uff0c\u6709\u663e\u8457\u4e34\u5e8a\u6548\u679c\u3002CBT-004\u4f5c\u4e3a\u4e00\u79cd\u5c0f\u5206\u5b50\u591a\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5728\u975e\u4e34\u5e8a\u836f\u6548\u52a8\u7269\u6a21\u578b\u4ee5\u53ca\u52a8\u7269\u6bd2\u7406\u5b9e\u9a8c\u4e2d\u5747\u663e\u793a\u51fa\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002<\/span><\/p><p class=\"MsoNormal\"><span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; font-family: '\u5fae\u8f6f\u96c5\u9ed1',sans-serif; mso-bidi-font-family: \u5fae\u8f6f\u96c5\u9ed1;\">\u6839\u636e\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u62a5\u544a\uff0c\u51682023\u5e74\u7684\u8840\u7ba1\u5316\u7751\u88c2\u6591\u60a3\u8005\u4eba\u53e3\u4e3a11.61\u4ebf\u4eba\uff0c\u5176\u4e2d\u7f8e\u56fd\u4e8e2023\u5e74\u7684\u8840\u7ba1\u5316\u7751\u88c2\u6591\u60a3\u8005\u4eba\u53e3\u4e3a4570\u4e07\u4eba\uff0c\u800c\u4e2d\u56fd\u4e8e2023\u5e74\u7684\u8840\u7ba1\u5316\u7751\u88c2\u6591\u60a3\u8005\u4eba\u53e3\u4e3a2070\u4e07\u4eba\u3002\u8840\u7ba1\u5316\u7751\u88c2\u6591\u836f\u7269\u7684\u5168\u7403\u5e02\u573a\u89c4\u6a21\u9884\u671f\u5c06\u4e8e2033\u5e74\u8fbe\u52301.5393\u4ebf\u7f8e\u5143\u3002\u8840\u7ba1\u5316\u7751\u88c2\u6591\u836f\u7269\u7684\u7f8e\u56fd\u53ca\u4e2d\u56fd\u5e02\u573a\u89c4\u6a21\u9884\u671f\u5c06\u4e8e2033\u5e74\u5206\u522b\u8fbe\u52309.406\u4ebf\u7f8e\u5143\u53ca9220\u4e07\u7f8e\u5143\u3002<\/span> <span lang=\"EN-HK\" style=\"font-size: 12.0pt; line-height: 107%; font-family: '\u5fae\u8f6f\u96c5\u9ed1',sans-serif; mso-bidi-font-family: \u5fae\u8f6f\u96c5\u9ed1;\">The patient population of vascularised pinguecula in China reached 207 million in 2023. The F&amp;S report also mentions that the global market size of vascularised pinguecula drug therapies is expected to reach US$1,539.3 million in 2033. The market size of vascularised pinguecula drug therapies in the United States and China are expected to reach US$940.6 million and US$92.2 million in 2033, respectively.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Cloudbreak Pharma Inc.&#8217;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":736,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cloudbreak Pharma Inc.&#039;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States - Cloudbreak Pharma, Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cloudbreak Pharma Inc.&#039;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States - Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"og:description\" content=\"Cloudbreak Pharma Inc.&#8217;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/\" \/>\n<meta property=\"og:site_name\" content=\"Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-15T08:41:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T09:08:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1363\" \/>\n\t<meta property=\"og:image:height\" content=\"575\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"James Gilbert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"James Gilbert\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/\"},\"author\":{\"name\":\"James Gilbert\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\"},\"headline\":\"Cloudbreak Pharma Inc.&#8217;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States\",\"datePublished\":\"2025-05-15T08:41:21+00:00\",\"dateModified\":\"2025-05-15T09:08:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/\"},\"wordCount\":488,\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"articleSection\":[\"News\"],\"inLanguage\":\"zh-CN\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/\",\"name\":\"Cloudbreak Pharma Inc.'s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States - Cloudbreak Pharma, Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"datePublished\":\"2025-05-15T08:41:21+00:00\",\"dateModified\":\"2025-05-15T09:08:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"width\":1363,\"height\":575},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cloudbreak Pharma Inc.&#8217;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"name\":\"Cloudbreak Pharma, Inc.\",\"description\":\"Seeing Life Better Through Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cloudbreakpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\",\"name\":\"Cloudbreak Pharma, Inc.\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"width\":824,\"height\":199,\"caption\":\"Cloudbreak Pharma, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\",\"name\":\"James Gilbert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"caption\":\"James Gilbert\"},\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/zh\\\/author\\\/jgdm18gmail-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cloudbreak Pharma Inc.'s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States - Cloudbreak Pharma, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/","og_locale":"zh_CN","og_type":"article","og_title":"Cloudbreak Pharma Inc.'s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States - Cloudbreak Pharma, Inc.","og_description":"Cloudbreak Pharma Inc.&#8217;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The [&hellip;]","og_url":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/","og_site_name":"Cloudbreak Pharma, Inc.","article_published_time":"2025-05-15T08:41:21+00:00","article_modified_time":"2025-05-15T09:08:43+00:00","og_image":[{"width":1363,"height":575,"url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","type":"image\/jpeg"}],"author":"James Gilbert","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"James Gilbert","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"3 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/#article","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/"},"author":{"name":"James Gilbert","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3"},"headline":"Cloudbreak Pharma Inc.&#8217;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States","datePublished":"2025-05-15T08:41:21+00:00","dateModified":"2025-05-15T09:08:43+00:00","mainEntityOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/"},"wordCount":488,"publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","articleSection":["News"],"inLanguage":"zh-CN"},{"@type":"WebPage","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/","url":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/","name":"Cloudbreak Pharma Inc.'s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States - Cloudbreak Pharma, Inc.","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/#primaryimage"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","datePublished":"2025-05-15T08:41:21+00:00","dateModified":"2025-05-15T09:08:43+00:00","breadcrumb":{"@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/#primaryimage","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","width":1363,"height":575},{"@type":"BreadcrumbList","@id":"https:\/\/cloudbreakpharma.com\/cloudbreak-pharma-inc-s-cbt-004-indicated-for-the-treatment-of-vascularised-pinguecula-has-completed-phase-ii-clinical-trials-in-the-united-states\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cloudbreakpharma.com\/"},{"@type":"ListItem","position":2,"name":"Cloudbreak Pharma Inc.&#8217;s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States"}]},{"@type":"WebSite","@id":"https:\/\/cloudbreakpharma.com\/#website","url":"https:\/\/cloudbreakpharma.com\/","name":"Cloudbreak Pharma, Inc.","description":"\u533b\u836f\u4f7f\u6211\u4eec\u80fd\u66f4\u597d\u7684\u89c6\u89c9\u4eab\u53d7\u751f\u6d3b","publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cloudbreakpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"https:\/\/cloudbreakpharma.com\/#organization","name":"Cloudbreak Pharma, Inc.","url":"https:\/\/cloudbreakpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","width":824,"height":199,"caption":"Cloudbreak Pharma, Inc."},"image":{"@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3","name":"James Gilbert","image":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","caption":"James Gilbert"},"url":"https:\/\/cloudbreakpharma.com\/zh\/author\/jgdm18gmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=915"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/915\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/736"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}